All peptides
DiagnosticFDA Approved

DOTATATE (Ga-68)

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Gallium-68 DOTATATE is a radiolabeled somatostatin analog consisting of an octapeptide (Tyr3-octreotate) conjugated to the macrocyclic chelator DOTA, which binds the positron-emitting radioisotope gallium-68. It exhibits high affinity for somatostatin receptor subtype 2, which is overexpressed on neuroendocrine tumor cells, enabling PET imaging of these malignancies.

Mechanism of Action

The 68-minute half-life of gallium-68 and the rapid pharmacokinetics of the peptide provide excellent tumor-to-background ratios within 1 to 2 hours post-injection.

Research Summary & Key Findings

The FDA approved gallium-68 DOTATATE (Netspot) in June 2016 for PET imaging of somatostatin receptor-positive neuroendocrine tumors based on studies demonstrating superior lesion detection compared to conventional imaging modalities including octreotide scintigraphy. A prospective multicenter trial published in the Journal of Nuclear Medicine (2013) showed 95.1% sensitivity for neuroendocrine tumor detection.

Clinical Status

FDA Approved

DOTATATE (Ga-68) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Diagnostic

Start Your Consultation

Get an AI-proposed DOTATATE (Ga-68) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply DOTATATE (Ga-68).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.